Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.70 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 11/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758316 | 0.84 | GRIA3 (0.97) | GRIA3GRIA4HPGDPOLBALDH1A1 | |
| SCHEMBL5760125 | 0.82 | GRIA3 (1.00) | GRIA3GRIA4HPGDPOLBALDH1A1 | |
| Farampator SCHEMBL677135 | 0.82 | GRIA3 (1.00) | GRIA3GRIA4HPGDPOLBALDH1A1 | |
| SCHEMBL5791567 | 0.82 | GRIA3 (0.72) | GRIA3GRIA4HPGDNAMPTALDH1A1 | |
| Cx-717 SCHEMBL243542 | 0.81 | GRIA3 (0.76) | GRIA3GRIA4HPGDPOLBALDH1A1 | |
| SCHEMBL5757878 | 0.80 | GRIA3 (0.74) | GRIA3GRIA4HPGDNAMPTPOLB | |
| SCHEMBL6575384 | 0.80 | GRIA3 (0.74) | GRIA3GRIA4HPGDNAMPTPOLB | |
| SCHEMBL5759402 | 0.79 | GRIA3 (0.72) | GRIA3GRIA4HPGDNAMPTALDH1A1 | |
| SCHEMBL25427592 | 0.78 | GRIA3 (0.44) | GRIA3GRIA4HPGDNAMPTALDH1A1 | |
| SCHEMBL5755898 | 0.78 | GRIA3 (0.70) | GRIA3GRIA4HPGDNAMPTENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039468-B2 | administering to subject having respiratory depression a positive allosteric AMPA receptor modulator; selected from the group consisting of: CX546, CX614, 1-(benzofurazan-5-ylcarbonyl)-4,4-difluoropiperidine, and 4-(benzofurazan-5-ylcarbonyl)morpholine | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-10-18 | — | — | US | claimed |
| EP-2061471-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | The Governors of the University of Alberta (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008025148-A1 | METHOD OF INHIBITION OF RESPIRATORY DEPRESSION USING POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2008-03-06 | — | — | WO | claimed |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2006-12-07 | — | — | US | claimed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-20240355686-A1 | Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers | RADIN DANIEL PIERCE (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | GRIA3 38/4885GRIA4 37/4885HPGD 2429/4885 |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | GRIA3 23/4885GRIA4 8/4885HPGD 1392/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885HPGD 1967/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | GRIA3 11/4885GRIA4 4/4885HPGD 1707/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885HPGD 1967/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | GRIA3 38/4885GRIA4 40/4885HPGD 2020/4885 |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | GRIN2A, GRIN1, GRIK5 | GRIA3 30/4885GRIA4 21/4885HPGD 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.